Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small Cell Lung Cancer
Alectinib at 300 mg twice daily seems an acceptable dose in East Asians with ALK-positive NSCLC. Notably, our data favor 300 mg twice daily in patients with lower body weight and no baseline brain metastasis, considering the more tolerable safety profiles and the potential to reduce medical costs.
Authors
- Hyun Ae Jung (ORCID: https://orcid.org/0000-0002-1583-4142)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5740-9654)
- Jinyong Kim
- M. Kim
- Se‐Hoon Lee (ORCID: https://orcid.org/0000-0002-9219-3350)
- Junkyu Kim (ORCID: https://orcid.org/0009-0001-4422-5434)
- Sehhoon Park (ORCID: https://orcid.org/0000-0001-9467-461X)
- Jin Seok Ahn
- Jong-Mu Sun
Institutions
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-04-24
- DOI
- https://doi.org/10.4143/crt.2024.1209
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00